A patient with heterozygous familial hypercholesterolemia is prescribed alirocumab. What is the primary mechanism of action of this medication?
-
A
It directly inhibits HMG-CoA reductase in the liver, reducing cholesterol synthesis.
-
B
It binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing its interaction with LDL receptors.
-
C
It blocks the intestinal absorption of cholesterol by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein.
-
D
It activates peroxisome proliferator-activated receptor alpha (PPAR-α), increasing lipoprotein lipase activity.